Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.

Zeltner N, Kohlbrenner E, Clément N, Weber T, Linden RM.

Gene Ther. 2010 Jul;17(7):872-9. doi: 10.1038/gt.2010.27. Epub 2010 Mar 25.

2.

[Recombinant adeno-associated virus vector related impurities].

Diao Y, Wang Q, Xiao W, Xu R.

Sheng Wu Gong Cheng Xue Bao. 2011 May;27(5):717-23. Review. Chinese.

PMID:
21845838
3.

Evaluation of risks related to the use of adeno-associated virus-based vectors.

Tenenbaum L, Lehtonen E, Monahan PE.

Curr Gene Ther. 2003 Dec;3(6):545-65. Review.

PMID:
14683451
4.

Intracellular transport of recombinant adeno-associated virus vectors.

Nonnenmacher M, Weber T.

Gene Ther. 2012 Jun;19(6):649-58. doi: 10.1038/gt.2012.6. Epub 2012 Feb 23. Review.

5.

New recombinant serotypes of AAV vectors.

Gao G, Vandenberghe LH, Wilson JM.

Curr Gene Ther. 2005 Jun;5(3):285-97. Review.

PMID:
15975006
6.

Receptor targeting of adeno-associated virus vectors.

Büning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J, Hallek M.

Gene Ther. 2003 Jul;10(14):1142-51. Review.

PMID:
12833123
7.

Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications.

Grieger JC, Samulski RJ.

Adv Biochem Eng Biotechnol. 2005;99:119-45. Review.

PMID:
16568890
8.

Engineering adeno-associated viruses for clinical gene therapy.

Kotterman MA, Schaffer DV.

Nat Rev Genet. 2014 Jul;15(7):445-51. doi: 10.1038/nrg3742. Epub 2014 May 20. Review.

9.

Adeno-associated virus serotypes: vector toolkit for human gene therapy.

Wu Z, Asokan A, Samulski RJ.

Mol Ther. 2006 Sep;14(3):316-27. Epub 2006 Jul 7. Review.

PMID:
16824801
10.

Gene therapy: recombinant adeno-associated virus vectors.

Smith-Arica JR, Bartlett JS.

Curr Cardiol Rep. 2001 Jan;3(1):43-9. Review.

PMID:
11139798
11.

Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification.

Miyake K, Miyake N, Yamazaki Y, Shimada T, Hirai Y.

J Nippon Med Sch. 2012;79(6):394-402. Review.

12.

Adeno-associated virus vectorology, manufacturing, and clinical applications.

Grieger JC, Samulski RJ.

Methods Enzymol. 2012;507:229-54. doi: 10.1016/B978-0-12-386509-0.00012-0. Review.

PMID:
22365777
13.

Gene therapy using adeno-associated virus vectors.

Daya S, Berns KI.

Clin Microbiol Rev. 2008 Oct;21(4):583-93. doi: 10.1128/CMR.00008-08. Review.

14.

Integration of adeno-associated virus (AAV) and recombinant AAV vectors.

McCarty DM, Young SM Jr, Samulski RJ.

Annu Rev Genet. 2004;38:819-45. Review.

PMID:
15568995
15.

Current issues in adeno-associated viral vector production.

Merten OW, Gény-Fiamma C, Douar AM.

Gene Ther. 2005 Oct;12 Suppl 1:S51-61. Review.

PMID:
16231056
16.

Clinical gene therapy using recombinant adeno-associated virus vectors.

Mueller C, Flotte TR.

Gene Ther. 2008 Jun;15(11):858-63. doi: 10.1038/gt.2008.68. Epub 2008 Apr 17. Review.

PMID:
18418415
18.

Versatility of AAV vectors for retinal gene transfer.

Surace EM, Auricchio A.

Vision Res. 2008 Feb;48(3):353-9. Epub 2007 Oct 17. Review.

19.

Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

Lu Y.

Stem Cells Dev. 2004 Feb;13(1):133-45. Review.

PMID:
15068701
20.

The state of the art of adeno-associated virus-based vectors in gene therapy.

Coura Rdos S, Nardi NB.

Virol J. 2007 Oct 16;4:99. Review. Erratum in: Virol J. 2010;7:12.

Items per page

Supplemental Content

Write to the Help Desk